Loading quotes...

Forecast

There is no analyst data available for this company.


  • Ambu A-S expects increase in revenue and profit in latest quarter

    Ambu A-S will release its quarterly results on 5 November 2026. Two analysts on average expect earnings per share of 0.862 DKK, up from 0.430 DKK in the year-ago quarter. Six analysts forecast revenue to rise 13.54 percent to around 1.66 billion DKK. For the past fiscal year, the analyst consensus is 2.40 DKK earnings per share and revenue of 6.44 billion DKK. » More on finanzen.net


  • Ambu share falls 15% after slightly missed quarter

    Ambu narrowly missed consensus expectations in the third quarter with EPS of $0.62 and revenue of $1.64bn, after which the stock fell 15.15% to $66.35. Organic revenue growth was 10.3%, driven by Endoscopy Solutions (+16%), and reported EBIT rose to 13.5%. Management raised the full-year forecast for organic growth to around 10% but warned of short-term margin pressures from higher selling expenses, currency and duties costs, and upcoming duty refunds that are expected to support the next quarter. » More on de.investing.com


  • Ambu forecasts significant quarterly growth in EPS and revenue

    Ambu will publish results on 26 August 2026 for the quarter ended 30 June 2026. Analysts on average expect EPS of 0.617 DKK, up 34.13% from 0.460 DKK a year earlier, and revenue of 1.65 billion DKK on average (+9.43% versus 1.51 billion DKK). For the current fiscal year, consensus estimates are 2.32 DKK earnings per share (previous year 2.29 DKK) and annual revenue of 6.47 billion DKK (previous year 6.04 billion DKK). » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2025, Ambu has already paid €0.0549 in dividends. The last payout was in December 2025.

Financials

In the last quarter, Ambu had revenue of €219.41m and net profit of €20.87m
(EUR) June 2026
YoY
Revenue 219.41m 8.62%
Gross profit 130.44m 9.72%
Net profit 20.87m 26.59%
EBITDA 42.95m 20.45%

Fundamentals

Metric Value
Market capitalization
€2.46bn
Number of shares
232.24m
52-week high/low
€14.58 - €7.53
Dividend yield
0.52%
Dividends TTM
€0.0549
Beta
1.38
P/E ratio
41.52
PEG ratio
0.98
P/B ratio
3.43
P/S ratio
2.95

Company profile

Ambu A/S entwickelt, produziert und vertreibt medizinische Geräte für Krankenhäuser, Kliniken und Rettungsdienste weltweit. Das Unternehmen bietet Gesundheitslösungen in den Bereichen Visualisierung, Anästhesie, Patientenüberwachung und Diagnostik. Das Unternehmen bietet Produkte für die Endoskopie, wie Bronchoskope und Monitore, und Produkte für die Neurologie, wie EEG- und EMG-Elektroden, EMG-geführte Injektionen und intraoperative Überwachungsprodukte. Darüber hinaus bietet das Unternehmen Produkte für die Kardiologie, bestehend aus EKG-Elektroden, sowie Produkte für das Atemwegsmanagement und die Anästhesie, wie Bronchoskope, Videolaryngoskope, doppel- und einlumige Tuben, endobronchiale Blocker, Kehlkopf- und Gesichtsmasken, Beatmungsbeutel und Wiederbelebungsgeräte. Darüber hinaus bietet das Unternehmen Befreiungsmanschetten, Kopf-Immobilizer, CPR-Atembarrieren und Übungspuppen an. Ambu A/S wurde 1937 gegründet und hat seinen Hauptsitz in Ballerup, Dänemark.

Name
Ambu
CEO
Britt Meelby Jensen
Headquarters Ballerup, cr
Denmark
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
11/02/2004
Employees 5,200

Ticker symbols

Exchange Symbol
Nasdaq Copenhagen
AMBU-B.CO
Pnk
AMBFF
Copenhagen
AMBU B.CO
Frankfurt
547A.F
Düsseldorf
547A.DU
London
0MJF.L
München
547A.MU
🍪

Parqet  uses cookies. Learn more